DOCSLIB.ORG

To Download a Copy of Agencyiq's COVID-19 Development Tracker

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
To Download a Copy of Agencyiq's COVID-19 Development Tracker Development tracker: The drugs and vaccines in development for COVID-19 The pharmaceutical and biopharmaceutical industry is scrambling to put products into development to potentially treat, cure or prevent COVID-19 infections. Based on a review by AgencyIQ of ClinicalTrials.gov, company announcements and media reports, there are at least 140 medical product candidates in various stages of testing to assess their potential effects against COVID-19 or SARS-CoV-2, the virus which causes the condition. Some have already been approved and are being assessed for their potential to treat COVID, while others are being repurposed from other late-stage development pipelines. Others are still in the very early stages of development and have not yet been tested in humans. Based on evidence from recent studies, the chances of clinical success are low. Of all drugs for infectious diseases that enter Phase 1 testing, just 26.7% go on to obtain approval. Just 31.6% of vaccines that enter Phase 1 testing go on to obtain approval. The size of the development pipeline and interest in COVID-19 may indicate that several of these products will go on to obtain approval, but the safety and efficacy of these products is far from guaranteed. As companies try to bring whatever compounds they have into clinical testing, it’s possible that few, if any, of these products will ultimately prove safe or effective. Highlights: 95+ 45+ 24+ 40+ Therapeutic medical Vaccines in development Products already approved Products already in clinical products in development for other indications development (6 vaccines, 34 therapies) Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Therapeutic Development Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase Ritonavir is an L- valine derivative that is an antiretroviral drug from the protease inhibitor class used to Abbott (HIV treat HIV infection and approval) prevent or treat AIDS. It is often used as a fixed- Abbott received approval AbbVie, dose combination with Approved in 1996 for for the treatment of HIV in Approved Ascletis, another protease HIV. Currently a piece of 1996 under the drug name for another Company Pharmstandard inhibitor, lopinavir. many clinical trials for Ritonavir Therapeutic Norvir. Many trials are indication; announcement , Gilead, Ritonavir is also used in COVID-19 treatments in looking at combinations of in clinical / PubChem Shionogi, combination with combination with other ritonavir and other drugs testing. Toyama dasabuvir sodium drugs. for treatment of COVID-19. Chemical, hydrate, ombitasvir and Janssen, paritaprevir (under the Biogen, Merck trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection and cirrhosis of the liver. The First Affiliated Approved Testing is taking place Hospital of Drug approved for The estimated study for another Reported in in China to assess Fujian Medical Fingolimod Therapeutics treatment of multiple completion date is July indication; media / treatment for COVID-19 University sclerosis (Novartis) 1st. in clinical Clinical Trials pneumonia. testing. Novartis Previous studies have First Affiliated shown the drug can treat Approved Currently in Phase II. Hospital of Testing taking place in H1N1 lung injury. for another Reported in Estimated study Wenzhou Thalidomide Therapeutic China for treatment of Thalidomide is approved indication; media / completion date is May Medical severe COVID-19 cases. in the US, though has a in clinical Clinical Trial 30th. University REMS due to causing birth testing. defects. Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase Approved FDA granted approval to for another Reported in Sildenafil Testing in China Currently in Phase III in Tongji Hospital Therapeutic Pfizer under the name indication; media / citrate currently. China. Viagra. in clinical Clinical Trial testing. Peking Union Medical Approved Currently being tested Reported in College Approved for many for another Cortico- in China and under a Trial estimated to Media / Hospital Therapeutic indications by the FDA indication; steroid phase III clinical trial for complete on April 25th Clinical Trial / including cancers. in clinical H1N1 WHO University of testing Oxford Novartis subsidiary Sandoz is donating up to 130 million doses of University of generic Minnesota hydroxychloroquine. Many groups are University of assessing the ability for Some clinical results are Oxford Company Chloroquine to treat already available but Approved announcement Chloroquine patients with Approved by the FDA for are inconclusive. HCQ for another Various / FDA / HHS / / Hydroxy- Therapeutic mild/moderate COVID- treatment of malaria was able to shorten indication; Chinese Reported in chloroquine 19 to reduce the (Novartis). recovery times in one in clinical research media / duration of symptoms study. testing sponsors Clinical Trial and decrease viral shedding. The FDA issued an EUA Novartis to allow the drug to be distributed from the Mylan national stockpile and used on hospitalized patients. Prior FDA approval for Approved Incyte’s Jakofi to treat Tongji Hospital Currently being tested Study in China set to for another Reported in “steroid-refractory acute Ruxolitinib Therapeutic in China for COVID-19 complete by end of indication; media / WHO / GVHD in adult and Incyte Corp. treatment. year in clinical Clinical Trial pediatric patients 12 years testing and older.” Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase Wuhan Infectious Approved Diseases Testing taking place in Merck (Schering) received No timeline. Clinical for another Hospital Peginterfero China. Also studying Reported in Therapeutic approval for the treatment trials currently occurring indication; n alfa-2b the effect in MERS Media / WHO of hepatitis C previously. in China. in clinical Eiger treatment. testing BioPharmaceut ic A recombinant humanized monoclonal Amgen received prior Approved Clinical trial is currently Reported in Qilu Hospital IgG1 antibody that approval from the FDA for another Therapeutic – recruiting in China. media / of Shandong Bevacizumab binds to and inhibits the under the name Avastin indication; antibodies Report out expected in Clinical Trial / University biologic activity of which is indicated for in clinical April. DrugBank human vascular cancer treatment. testing endothelial growth factor (VEGF). Gilead Clinical trial currently taking place in China Sichian for COVID-19 Approved Academy of Approved by the FDA in treatment. It works as a for another Medical Emtricitabine Therapeutic - 2004 under name Truvada WHO / Clinical “Non-nucleoside No timeline indication; Sciences & , tenofovir antiviral (Gilead) to treat/prevent Trial reverse transcriptase in clinical Sichian HIV-1. inhibitor and testing Provincial nucleotide reverse People’s transcriptase inhibitor” Hospital Roche BARDA Approved by FDA under No timeline, but further Approved Roche is starting a the name than others studying the for another Company First Affiliated Therapeutic – Phase III clinical trial for Actemra/RoActemra Tocilizumab same drug in other indication; announcement Hospital of the antibodies treatment of COVID-19 previously, for the countries. Currently in in clinical / Clinical Trial University pneumonia. indication of rheumatoid Phase III testing of Science and artritis. Technology of China Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase The company already markets iNO as INOmax in the US to treat term and The company is near-term newborns exploring inhaled nitric suffering from hypoxic Currently working with oxide (iNO) as a respiratory failure caused FDA and other Approved Company Inhaled nitric supportive measure for Mallinckrodt Therapeutic by pulmonary regulatory agencies to for another announcement oxide (ino) COVID-19, particularly hypertension. Additionally, explore the treatment indication. / PubChem for patients with iNO was used in a study to possibility. pulmonary treat six SARS-CoV patients complications. and showed improvements compared to controls. Baloxavir marboxil was originally developed by Shionogi Co. and Roche for influenza A and Previously approved influenza B infections. The under another Baloxavir is an inhibitor drug was initially approved indication. Currently in Approved of the influenza cap- for use in Japan in Reported in clinical testing in China for another Baloxavir dependent February 2018. It was media / Roche Therapeutic in combination with indication; marboxil endonuclease enzyme approved by the FDA on PubChem / Favipiravir at The First in clinical and is used as therapy October 24, 2018, for the Clinical Trials Affiliated Hospital, testing of influenza A and B. treatment of acute Zhejiang University uncomplicated influenza in School of Medicine. patients 12 years of age or older who have been symptomatic for no more than 48 hours. Interferon-beta is a form of recombinant A clinical trial is BIOGEN received approval human interferon used ongoing in France, Approved in the US for this drug to Company to slow disease sponsored by the for another Interferon treat multiple sclerosis. A announceme Merck KGaA
Load more

Recommended publications
  • Antioxidant Potential of Antiviral Drug Umifenovir
    molecules Article Antioxidant Potential of Antiviral Drug Umifenovir Elena V. Proskurnina 1,*, Dmitry Yu. Izmailov 2, Madina M. Sozarukova 3, Tatiana A. Zhuravleva 2, Irina A. Leneva 4 and Artem A. Poromov 4 1 Research Centre for Medical Genetics, ul. Moskvorechye 1, Moscow 115522, Russia 2 Faculty of Fundamental Medicine, Lomonosov Moscow State University, Lomonosovsky prospekt 27-1, Moscow 119234, Russia; [email protected] (D.Y.I.); [email protected] (T.A.Z.) 3 Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninsky prospekt 31, Moscow 119991, Russia; [email protected] 4 Department of Experimental Virology, Mechnikov Research Institute for Vaccines and Sera, Malyi Kazennyi pereulok 5a, Moscow 105064, Russia; [email protected] (I.A.L.); [email protected] (A.A.P.) * Correspondence: [email protected]; Tel.: +7-(499)-612-8193 Received: 21 February 2020; Accepted: 28 March 2020; Published: 30 March 2020 Abstract: Free radical reactions play an important role in biological functions of living systems. The balance between oxidants and antioxidants is necessary for the normal homeostasis of cells and organisms. Experimental works demonstrate the role of oxidative stress that is caused by influenza virus as well as the toxic effects of some antiviral drugs. Therefore, antiviral drugs should be characterized by its pro- and antioxidant activity, because it can affect its therapeutic efficiency. The aim of the study was to quantify the antioxidant capacity and propose the mechanism of the antioxidant effect of the antiviral drug Umifenovir (Arbidol®). The kinetic chemiluminescence with the 2,2’-azobis (2-amidinopropane) dihydrochloride + luminol system was used to quantify the antioxidant capacity of Umifenovir relative to the standard compound Trolox.
    [Show full text]
  • Microorganisms-07-00521-V2.Pdf
    microorganisms Review Are Community Acquired Respiratory Viral Infections an Underestimated Burden in Hematology Patients? Cristian-Marian Popescu 1,* , Aurora Livia Ursache 2, Gavriela Feketea 1 , Corina Bocsan 3, Laura Jimbu 1, Oana Mesaros 1, Michael Edwards 4,5, Hongwei Wang 6, Iulia Berceanu 7, Alexandra Neaga 1 and Mihnea Zdrenghea 1,7,* 1 Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 8 Babes str., 400012 Cluj-Napoca, Romania; [email protected] (G.F.); [email protected] (L.J.); [email protected] (O.M.); [email protected] (A.N.) 2 The Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine, Calea Mănăs, tur 3-5, 400372 Cluj-Napoca, Romania; [email protected] 3 Department of Pharmacology, Toxicology and Clinical Pharmacology, Iuliu Ha¸tieganuUniversity of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania; [email protected] 4 National Heart and Lung Institute, St Mary’s Campus, Imperial College London, London W2 1PG, UK; [email protected] 5 Medical Research Council (MRC) and Asthma UK Centre in Allergic Mechanisms of Asthma, London W2 1PG, UK 6 School of Medicine, Nanjing University, 22 Hankou Road, Nanjing 210093, China; [email protected] 7 Department of Hematology, Ion Chiricuta Oncology Institute, 34-36 Republicii Street, 400015 Cluj-Napoca, Romania; [email protected] * Correspondence: [email protected] (C.-M.P.); [email protected] (M.Z.) Received: 8 October 2019; Accepted: 31 October 2019; Published: 2 November 2019 Abstract: Despite a plethora of studies demonstrating significant morbidity and mortality due to community-acquired respiratory viral (CRV) infections in intensively treated hematology patients, and despite the availability of evidence-based guidelines for the diagnosis and management of respiratory viral infections in this setting, there is no uniform inclusion of respiratory viral infection management in the clinical hematology routine.
    [Show full text]
  • Emerging Role of Mucosal Vaccine in Preventing Infection with Avian Influenza a Viruses
    viruses Review Emerging Role of Mucosal Vaccine in Preventing Infection with Avian Influenza A Viruses Tong Wang 1, Fanhua Wei 2 and Jinhua Liu 1,* 1 Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China; [email protected] 2 College of Agriculture, Ningxia University, Yinchuan 750021, China; [email protected] * Correspondence: [email protected] Received: 22 July 2020; Accepted: 5 August 2020; Published: 7 August 2020 Abstract: Avian influenza A viruses (AIVs), as a zoonotic agent, dramatically impacts public health and the poultry industry. Although low pathogenic avian influenza virus (LPAIV) incidence and mortality are relatively low, the infected hosts can act as a virus carrier and provide a resource pool for reassortant influenza viruses. At present, vaccination is the most effective way to eradicate AIVs from commercial poultry. The inactivated vaccines can only stimulate humoral immunity, rather than cellular and mucosal immune responses, while failing to effectively inhibit the replication and spread of AIVs in the flock. In recent years, significant progresses have been made in the understanding of the mechanisms underlying the vaccine antigen activities at the mucosal surfaces and the development of safe and efficacious mucosal vaccines that mimic the natural infection route and cut off the AIVs infection route. Here, we discussed the current status and advancement on mucosal immunity, the means of establishing mucosal immunity, and finally a perspective for design of AIVs mucosal vaccines. Hopefully, this review will help to not only understand and predict AIVs infection characteristics in birds but also extrapolate them for distinction or applicability in mammals, including humans.
    [Show full text]
  • Immunomodulators Under Evaluation for the Treatment of COVID-19
    Immunomodulators Under Evaluation for the Treatment of COVID-19 Last Updated: August 4, 2021 Summary Recommendations See Therapeutic Management of Hospitalized Adults with COVID-19 for the COVID-19 Treatment Guidelines Panel’s (the Panel) recommendations on the use of the following immunomodulators for patients according to their disease severity: • Baricitinib with dexamethasone • Dexamethasone • Tocilizumab with dexamethasone Additional Recommendations There is insufficient evidence for the Panel to recommend either for or against the use of the following immunomodulators for the treatment of COVID-19: • Colchicine for nonhospitalized patients • Fluvoxamine • Granulocyte-macrophage colony-stimulating factor inhibitors for hospitalized patients • Inhaled budesonide • Interleukin (IL)-1 inhibitors (e.g., anakinra) • Interferon beta for the treatment of early (i.e., <7 days from symptom onset) mild to moderate COVID-19 • Sarilumab for patients who are within 24 hours of admission to the intensive care unit (ICU) and who require invasive mechanical ventilation, noninvasive ventilation, or high-flow oxygen (>0.4 FiO2/30 L/min of oxygen flow) The Panel recommends against the use of the following immunomodulators for the treatment of COVID-19, except in a clinical trial: • Baricitinib with tocilizumab (AIII) • Interferons (alfa or beta) for the treatment of severely or critically ill patients with COVID-19 (AIII) • Kinase inhibitors: • Bruton’s tyrosine kinase inhibitors (e.g., acalabrutinib, ibrutinib, zanubrutinib) (AIII) • Janus kinase inhibitors other than baricitinib (e.g., ruxolitinib, tofacitinib) (AIII) • Non-SARS-CoV-2-specific intravenous immunoglobulin (IVIG) (AIII). This recommendation should not preclude the use of IVIG when it is otherwise indicated for the treatment of complications that arise during the course of COVID-19.
    [Show full text]
  • Current and Novel Approaches in Influenza Management
    Review Current and Novel Approaches in Influenza Management Erasmus Kotey 1,2,3 , Deimante Lukosaityte 4,5, Osbourne Quaye 1,2 , William Ampofo 3 , Gordon Awandare 1,2 and Munir Iqbal 4,* 1 West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Legon, Accra P.O. Box LG 54, Ghana; [email protected] (E.K.); [email protected] (O.Q.); [email protected] (G.A.) 2 Department of Biochemistry, Cell & Molecular Biology, University of Ghana, Legon, Accra P.O. Box LG 54, Ghana 3 Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra P.O. Box LG 581, Ghana; [email protected] 4 The Pirbright Institute, Ash Road, Pirbright, Woking, Surrey GU24 0NF, UK; [email protected] 5 The University of Edinburgh, Edinburgh, Scotland EH25 9RG, UK * Correspondence: [email protected] Received: 20 May 2019; Accepted: 17 June 2019; Published: 18 June 2019 Abstract: Influenza is a disease that poses a significant health burden worldwide. Vaccination is the best way to prevent influenza virus infections. However, conventional vaccines are only effective for a short period of time due to the propensity of influenza viruses to undergo antigenic drift and antigenic shift. The efficacy of these vaccines is uncertain from year-to-year due to potential mismatch between the circulating viruses and vaccine strains, and mutations arising due to egg adaptation. Subsequently, the inability to store these vaccines long-term and vaccine shortages are challenges that need to be overcome. Conventional vaccines also have variable efficacies for certain populations, including the young, old, and immunocompromised.
    [Show full text]
  • TITLE PAGE COVID-19 Treatment
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 26 March 2020 doi:10.20944/preprints202003.0378.v1 Peer-reviewed version available at International Journal of Antimicrobial Agents 2020; doi:10.1016/j.ijantimicag.2020.106080 TITLE PAGE COVID-19 Treatment: Close to a Cure? – A Rapid Review of Pharmacotherapies for the Novel Coronavirus 1. Yang Song, PharmD, BCPS Department of Pharmacy Services CHI Franciscan Health-St. Joseph Medical Center Tacoma, WA 98405 [email protected] 2. Min Zhang, PharmD, BCPS Department of Pharmacy Services Boston Medical Center Boston, MA 02118 3. Ling Yin, PharmD, PhD, BCPS, BCOP Department of Pharmacy Services AdventHealth Celebration Cancer Institute Celebration, FL 34747 4. Kunkun Wang, PharmD Department of Pharmacy Services Fairbanks Memorial Hospital Fairbanks, AK 99701 5. Yiyi Zhou, PharmD Department of Pharmacy Services Beijing United Family Hospital Beijing, China 100016 6. Mi Zhou, MM Department of Pharmacy Services Children’s Hospital of Soochow University Suzhou, China 215000 7. Yun Lu, PharmD, MS Associate Clinical Professor, University of Minnesota Department of Pharmacy Services Hennepin County Medical Center Minneapolis, MN 55415 1 © 2020 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 26 March 2020 doi:10.20944/preprints202003.0378.v1 Peer-reviewed version available at International Journal of Antimicrobial Agents 2020; doi:10.1016/j.ijantimicag.2020.106080 Abstract Currently, there is no specific treatment for COVID-19 proven by clinical trials. WHO and CDC guidelines therefore endorse supportive care only. However, frontline clinicians have been applying several virus- based and host-based therapeutics in order to combat SARS-CoV-2.
    [Show full text]
  • Development and Effects of Influenza Antiviral Drugs
    molecules Review Development and Effects of Influenza Antiviral Drugs Hang Yin, Ning Jiang, Wenhao Shi, Xiaojuan Chi, Sairu Liu, Ji-Long Chen and Song Wang * Key Laboratory of Fujian-Taiwan Animal Pathogen Biology, College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou 350002, China; [email protected] (H.Y.); [email protected] (N.J.); [email protected] (W.S.); [email protected] (X.C.); [email protected] (S.L.); [email protected] (J.-L.C.) * Correspondence: [email protected] Abstract: Influenza virus is a highly contagious zoonotic respiratory disease that causes seasonal out- breaks each year and unpredictable pandemics occasionally with high morbidity and mortality rates, posing a great threat to public health worldwide. Besides the limited effect of vaccines, the problem is exacerbated by the lack of drugs with strong antiviral activity against all flu strains. Currently, there are two classes of antiviral drugs available that are chemosynthetic and approved against influenza A virus for prophylactic and therapeutic treatment, but the appearance of drug-resistant virus strains is a serious issue that strikes at the core of influenza control. There is therefore an urgent need to develop new antiviral drugs. Many reports have shown that the development of novel bioactive plant extracts and microbial extracts has significant advantages in influenza treat- ment. This paper comprehensively reviews the development and effects of chemosynthetic drugs, plant extracts, and microbial extracts with influenza antiviral activity, hoping to provide some refer- ences for novel antiviral drug design and promising alternative candidates for further anti-influenza drug development.
    [Show full text]
  • High-Throughput Human Primary Cell-Based Airway Model for Evaluating Infuenza, Coronavirus, Or Other Respira- Tory Viruses in Vitro
    www.nature.com/scientificreports OPEN High‑throughput human primary cell‑based airway model for evaluating infuenza, coronavirus, or other respiratory viruses in vitro A. L. Gard1, R. J. Luu1, C. R. Miller1, R. Maloney1, B. P. Cain1, E. E. Marr1, D. M. Burns1, R. Gaibler1, T. J. Mulhern1, C. A. Wong1, J. Alladina3, J. R. Coppeta1, P. Liu2, J. P. Wang2, H. Azizgolshani1, R. Fennell Fezzie1, J. L. Balestrini1, B. C. Isenberg1, B. D. Medof3, R. W. Finberg2 & J. T. Borenstein1* Infuenza and other respiratory viruses present a signifcant threat to public health, national security, and the world economy, and can lead to the emergence of global pandemics such as from COVID‑ 19. A barrier to the development of efective therapeutics is the absence of a robust and predictive preclinical model, with most studies relying on a combination of in vitro screening with immortalized cell lines and low‑throughput animal models. Here, we integrate human primary airway epithelial cells into a custom‑engineered 96‑device platform (PREDICT96‑ALI) in which tissues are cultured in an array of microchannel‑based culture chambers at an air–liquid interface, in a confguration compatible with high resolution in‑situ imaging and real‑time sensing. We apply this platform to infuenza A virus and coronavirus infections, evaluating viral infection kinetics and antiviral agent dosing across multiple strains and donor populations of human primary cells. Human coronaviruses HCoV‑NL63 and SARS‑CoV‑2 enter host cells via ACE2 and utilize the protease TMPRSS2 for spike protein priming, and we confrm their expression, demonstrate infection across a range of multiplicities of infection, and evaluate the efcacy of camostat mesylate, a known inhibitor of HCoV‑NL63 infection.
    [Show full text]
  • Study Protocol
    NCT03376321 Janssen Research & Development * Clinical Protocol A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection Protocol 63623872FLZ3001; Phase 3 AMENDMENT 2 JNJ-63623872-ZCD Pimodivir *Janssen Research & Development is a global organization that operates through different legal entities in various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen Biologics, BV; Janssen-Cilag International NV; Janssen Pharmaceutica NV; Janssen, Inc; Janssen Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout the protocol to represent these various legal entities; the sponsor is identified on the Contact Information page that accompanies the protocol. This study will be conducted under US Food & Drug Administration IND regulations (21 CFR Part 312). EudraCT NUMBER: 2017-002156-84 Status: Approved Date: 11 June 2019 Prepared by: Janssen Research & Development, a division of Janssen Pharmaceutica NV EDMS number: EDMS-ERI-121941709, 10.0 GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory requirements. Confidentiality Statement The information in this document contains trade secrets and commercial information that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them.
    [Show full text]
  • Virus-Host Interactomics: New Insights and Opportunities for Antiviral Drug Discovery
    de Chassey et al. Genome Medicine 2014, 6:115 http://genomemedicine.com/content/6/11/115 REVIEW Virus-host interactomics: new insights and opportunities for antiviral drug discovery Benoît de Chassey1, Laurène Meyniel-Schicklin1, Jacky Vonderscher1, Patrice André2,3,4 and Vincent Lotteau3,4* Abstract The current therapeutic arsenal against viral infections remains limited, with often poor efficacy and incomplete coverage, and appears inadequate to face the emergence of drug resistance. Our understanding of viral biology and pathophysiology and our ability to develop a more effective antiviral arsenal would greatly benefit from a more comprehensive picture of the events that lead to viral replication and associated symptoms. Towards this goal, the construction of virus-host interactomes is instrumental, mainly relying on the assumption that a viral infection at the cellular level can be viewed as a number of perturbations introduced into the host protein network when viral proteins make new connections and disrupt existing ones. Here, we review advances in interactomic approaches for viral infections, focusing on high-throughput screening (HTS) technologies and on the generation of high-quality datasets. We show how these are already beginning to offer intriguing perspectives in terms of virus-host cell biology and the control of cellular functions, and we conclude by offering a summary of the current situation regarding the potential development of host-oriented antiviral therapeutics. Introduction the virus life-cycle. These proteins
    [Show full text]
  • Journal Pre-Proof
    Journal Pre-proof Ongoing Clinical Trials for the Management of the COVID-19 Pandemic M.P. Lythgoe, P. Middleton PII: S0165-6147(20)30070-5 DOI: https://doi.org/10.1016/j.tips.2020.03.006 Reference: TIPS 1706 To appear in: Trends in Pharmacological Sciences Please cite this article as: M.P. Lythgoe and P. Middleton, Ongoing Clinical Trials for the Management of the COVID-19 Pandemic, Trends in Pharmacological Sciences (2020), https://doi.org/10.1016/j.tips.2020.03.006 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Published by Elsevier. Journal Pre-proof Ongoing Clinical Trials for the Management of the COVID-19 Pandemic *MP Lythgoe1 & *P Middleton2 1Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, W120HS, London, UK 2 Department of Metabolism, Digestion & Reproduction, Imperial College London, St Marys Hospital, Praed Street, W21NY, London UK *Equal contribution Corresponding Email: [email protected] Key words: Coronavirus, SARS-CoV-2, COVID-19, 2019-nCoV, pandemic ABSTRACT COVID-19 has rapidly developed into a worldwide pandemic causing a significant health and economic burden.
    [Show full text]
  • SARS-Cov-2: Current Therapeutics Human and Veterinary Medicine
    Iowa State University Capstones, Theses and Creative Components Dissertations Fall 2020 SARS-CoV-2: Current Therapeutics Human and Veterinary Medicine Andrea Garcia Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/creativecomponents Part of the Animal Diseases Commons, Other Veterinary Medicine Commons, Pharmacology Commons, Respiratory Tract Diseases Commons, and the Virus Diseases Commons Recommended Citation Garcia, Andrea, "SARS-CoV-2: Current Therapeutics Human and Veterinary Medicine" (2020). Creative Components. 643. https://lib.dr.iastate.edu/creativecomponents/643 This Creative Component is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Creative Components by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. SARS-CoV-2: Current Therapeutics Human and Veterinary Medicine Abstract The Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV-2, was first reported in Wuhan City, China, in December 2019. Health and environmental risk factors are crucial in this current pandemic, yet it is essential to note that even though individuals of all ages are susceptive to this virus, there are risk factors associated with developing the severe disease. It is also eminent to establish the human-animal interaction by tackling important past pathogenic viruses such as SARS-CoV and MERS-CoV and its zoonotic links. In need of a clinically established management for this outbreak, approved drugs' therapeutic interventions could help treat this disease, targeting its replication. The need to resolve the current pandemic of COVID-19 epitomizes the need for a different approach, drug repurposing.
    [Show full text]